Candida auris: outbreak fungal pathogen in COVID-19 pandemic:: a systematic review and meta-analysis

Kamran Bagheri Lankarani; Maryam Akbari; Reza Tahrizi; Mohebat Vali; Eghbal Sekhavati; Seyed Taghi Heydari; Hossein Khodadadi; Fariba Ahmadizar

doi:10.18502/ijm.v14i3.9753

Candida auris: outbreak fungal pathogen in COVID-19 pandemic: a systematic review and meta-analysis

Kamran Bagheri Lankarani
, Maryam Akbari^*
, Reza Tahrizi
, Mohebat Vali
, Eghbal Sekhavati
, Seyed Taghi Heydari
, Hossein Khodadadi
, Fariba Ahmadizar

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

1 Downloads (Pure)

Abstract

BACKGROUND AND OBJECTIVES: Candida auris (C. auris) is the first fungal pathogen considered a global health threat. Because, C. auris is associated with multidrug resistance and associated diseases such as diabetes, sepsis, lung and kidney disease. This study investigated the prevalence and mortality of C. auris infection during Covid-19 pandemic.

MATERIALS AND METHODS: Databases were searched for peer-reviewed articles published in the English language up to Jan 18, 2022. Heterogeneity across studies was evaluated using Cochrane's Q test and the I2 index. The pooled point prevalences and their corresponding 95% confidence intervals (CIs) were estimated usingthe random-effects model.

RESULTS: In our meta-analysis, 11 eligible articles were included. The total pooled prevalence estimation of C. auris infection among COVID-19 patients was 13% (95% CI: 8%, 19%). The estimated pooled mortality rate of C. auris infection was 37% (95% CI: 15%, 61%). In terms of specific conditions, the pooled risk of mortality was higher in people with diabetes 65% (95% CI: 0.45%, 83%), in cases with >21 days admission inintensive care unit (ICU) 44% (95% CI: 21%, 0.68%), and after receiving steroids 43% (95% CI: 18%, 69%).

CONCLUSION: Our study highlights the high prevalence rate of C. auris infection, particularly among people with a history of metabolic disorders.

Original language	English
Pages (from-to)	276-284
Number of pages	9
Journal	IRANIAN JOURNAL OF MICROBIOLOGY
Volume	14
Issue number	3
DOIs	https://doi.org/10.18502/ijm.v14i3.9753
Publication status	Published - Jun 2022
Externally published	Yes

Keywords

COVID-19
Candida auris infection
Disease outbreaks
Meta-analysis

Access to Document

10.18502/ijm.v14i3.9753Licence: CC BY-NC

3355-Article Text-15914-1-10-20220613Final published version, 791 KBLicence: CC BY-NC

Cite this

@article{0b6771824c2848e6a287485ff9c694d1,

title = "Candida auris: outbreak fungal pathogen in COVID-19 pandemic:: a systematic review and meta-analysis",

abstract = "BACKGROUND AND OBJECTIVES: Candida auris (C. auris) is the first fungal pathogen considered a global health threat. Because, C. auris is associated with multidrug resistance and associated diseases such as diabetes, sepsis, lung and kidney disease. This study investigated the prevalence and mortality of C. auris infection during Covid-19 pandemic. MATERIALS AND METHODS: Databases were searched for peer-reviewed articles published in the English language up to Jan 18, 2022. Heterogeneity across studies was evaluated using Cochrane's Q test and the I2 index. The pooled point prevalences and their corresponding 95\% confidence intervals (CIs) were estimated usingthe random-effects model.RESULTS: In our meta-analysis, 11 eligible articles were included. The total pooled prevalence estimation of C. auris infection among COVID-19 patients was 13\% (95\% CI: 8\%, 19\%). The estimated pooled mortality rate of C. auris infection was 37\% (95\% CI: 15\%, 61\%). In terms of specific conditions, the pooled risk of mortality was higher in people with diabetes 65\% (95\% CI: 0.45\%, 83\%), in cases with >21 days admission inintensive care unit (ICU) 44\% (95\% CI: 21\%, 0.68\%), and after receiving steroids 43\% (95\% CI: 18\%, 69\%). CONCLUSION: Our study highlights the high prevalence rate of C. auris infection, particularly among people with a history of metabolic disorders. ",

keywords = "COVID-19, Candida auris infection, Disease outbreaks, Meta-analysis",

author = "Lankarani, \{Kamran Bagheri\} and Maryam Akbari and Reza Tahrizi and Mohebat Vali and Eghbal Sekhavati and Heydari, \{Seyed Taghi\} and Hossein Khodadadi and Fariba Ahmadizar",

note = "Funding Information: The authors wish to thank Shiraz University of Medical Sciences for support us in doing this research. Publisher Copyright: {\textcopyright} 2022 The Authors. Published by Tehran University of Medical Sciences. This work is licensed under a Creative Commons Attribution-Non Commercial.",

year = "2022",

month = jun,

doi = "10.18502/ijm.v14i3.9753",

language = "English",

volume = "14",

pages = "276--284",

journal = "IRANIAN JOURNAL OF MICROBIOLOGY",

issn = "2008-3289",

publisher = "Tehran University of Medical Sciences",

number = "3",

}

TY - JOUR

T1 - Candida auris: outbreak fungal pathogen in COVID-19 pandemic:

T2 - a systematic review and meta-analysis

AU - Lankarani, Kamran Bagheri

AU - Akbari, Maryam

AU - Tahrizi, Reza

AU - Vali, Mohebat

AU - Sekhavati, Eghbal

AU - Heydari, Seyed Taghi

AU - Khodadadi, Hossein

AU - Ahmadizar, Fariba

N1 - Funding Information: The authors wish to thank Shiraz University of Medical Sciences for support us in doing this research. Publisher Copyright: © 2022 The Authors. Published by Tehran University of Medical Sciences. This work is licensed under a Creative Commons Attribution-Non Commercial.

PY - 2022/6

Y1 - 2022/6

N2 - BACKGROUND AND OBJECTIVES: Candida auris (C. auris) is the first fungal pathogen considered a global health threat. Because, C. auris is associated with multidrug resistance and associated diseases such as diabetes, sepsis, lung and kidney disease. This study investigated the prevalence and mortality of C. auris infection during Covid-19 pandemic. MATERIALS AND METHODS: Databases were searched for peer-reviewed articles published in the English language up to Jan 18, 2022. Heterogeneity across studies was evaluated using Cochrane's Q test and the I2 index. The pooled point prevalences and their corresponding 95% confidence intervals (CIs) were estimated usingthe random-effects model.RESULTS: In our meta-analysis, 11 eligible articles were included. The total pooled prevalence estimation of C. auris infection among COVID-19 patients was 13% (95% CI: 8%, 19%). The estimated pooled mortality rate of C. auris infection was 37% (95% CI: 15%, 61%). In terms of specific conditions, the pooled risk of mortality was higher in people with diabetes 65% (95% CI: 0.45%, 83%), in cases with >21 days admission inintensive care unit (ICU) 44% (95% CI: 21%, 0.68%), and after receiving steroids 43% (95% CI: 18%, 69%). CONCLUSION: Our study highlights the high prevalence rate of C. auris infection, particularly among people with a history of metabolic disorders.

AB - BACKGROUND AND OBJECTIVES: Candida auris (C. auris) is the first fungal pathogen considered a global health threat. Because, C. auris is associated with multidrug resistance and associated diseases such as diabetes, sepsis, lung and kidney disease. This study investigated the prevalence and mortality of C. auris infection during Covid-19 pandemic. MATERIALS AND METHODS: Databases were searched for peer-reviewed articles published in the English language up to Jan 18, 2022. Heterogeneity across studies was evaluated using Cochrane's Q test and the I2 index. The pooled point prevalences and their corresponding 95% confidence intervals (CIs) were estimated usingthe random-effects model.RESULTS: In our meta-analysis, 11 eligible articles were included. The total pooled prevalence estimation of C. auris infection among COVID-19 patients was 13% (95% CI: 8%, 19%). The estimated pooled mortality rate of C. auris infection was 37% (95% CI: 15%, 61%). In terms of specific conditions, the pooled risk of mortality was higher in people with diabetes 65% (95% CI: 0.45%, 83%), in cases with >21 days admission inintensive care unit (ICU) 44% (95% CI: 21%, 0.68%), and after receiving steroids 43% (95% CI: 18%, 69%). CONCLUSION: Our study highlights the high prevalence rate of C. auris infection, particularly among people with a history of metabolic disorders.

KW - COVID-19

KW - Candida auris infection

KW - Disease outbreaks

KW - Meta-analysis

UR - https://www.scopus.com/pages/publications/85134413535

U2 - 10.18502/ijm.v14i3.9753

DO - 10.18502/ijm.v14i3.9753

M3 - Comment/Letter to the editor

C2 - 37124855

SN - 2008-3289

VL - 14

SP - 276

EP - 284

JO - IRANIAN JOURNAL OF MICROBIOLOGY

JF - IRANIAN JOURNAL OF MICROBIOLOGY

IS - 3

ER -

Candida auris: outbreak fungal pathogen in COVID-19 pandemic: a systematic review and meta-analysis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this